The Successor-2 Study for relapsed or refractory multiple myeloma (RRMM)
- kati810
- Mar 5
- 2 min read
All4Cure is providing information about clinical trial for relapsed multiple myeloma called Successor-2 Study
The purpose of this study is to compare the efficacy and safety of an investigational drug called mezigdomide (CC-92480) with FDA-approved drugs carfilzomib and dexamethasone (MeziKD) versus an FDA-approved regimen of carfilzomib and dexamethasone (Kd). The open-label trial is recruiting patients with relapsed or refractory multiple myeloma (RRMM) who received at least 1 prior line of therapy and who have had prior lenalidomide (Revlimid) and anti-CD38 monoclonal antibody (mAb) exposure.
If eligible, you may receive:
Study-related medical care
Study-related lab work and procedures
You will not be charged for the study drug, and you may also be eligible for reimbursement of some costs, such as travel or transportation, depending on your location.
Eligible participants must:
Be 18 years of age or older
Have an RRMM diagnosis
Have received at least 1 prior line of antimyeloma therapy
Have received prior treatment with lenalidomide and at least 2 cycles of an anti-CD38 monoclonal antibody (mAb) Note: Those intolerant of any anti-CD38 mAb and who have received less than 2 cycles are still eligible.
Have never received treatment with mezigdomide or carfilzomib
Other eligibility criteria may apply.
Study participation
The length of participation in the Successor-2 Study will vary for each participant. Approximately 525 participants will be enrolled in the study and will be assigned at random to receive either mezigdomide with carfilzomib and dexamethasone or the combination therapy of carfilzomib and dexamethasone.
The Successor-2 Study consists of:
Screening period: The study doctor will perform tests to determine if an individual is eligible to enroll in the study. This period may last up to 28 days.
Study treatment period: Study participants will be assigned at random to receive either mezigdomide with IV carfilzomib and dexamethasone (Study Treatment Arm A), or IV carfilzomib and dexamethasone (Study Treatment Arm B), in cycles lasting 28 days. Participants assigned to Study Treatment Arm A will have 3 study site visits per cycle for Cycles 1–12 and 2 study site visits per cycle for all cycles after Cycle 13. Participants assigned to Study Treatment Arm B will have either 3 or 6 visits per cycle, depending on the treatment frequency the physician selects (infusion once or twice per week).
Post–study treatment follow-up period: At the end of treatment and 4 weeks after the end of treatment, participants will be required to return for a follow-up visit. If the study treatment ends early, participants will be required to return to the study site for a health evaluation.
Progression-free survival (PFS) follow-up: Participants who discontinue their study treatment for any reason other than their RRMM worsening, or withdrawal of consent, will have study visits every 28 days to continue monitoring their RRMM status. If a participant’s RRMM worsens, a PFS Discontinuation Visit will be performed.
Long-term follow-up: Study participants will have study visits every 4 months. These visits can be done through telemedicine.
Please view the PDF attached for more information.
If you want to learn more, please get in touch with All4Cure at trial@all4cure.com.
Please note: All4Cure has a commercial relationship with Celgene, a Bristol Myers Squibb
company, the manufacturer of mezigdomide.
